PAS-7 (Proteasome subunit alpha type-3) is the C. elegans ortholog of the human PSMA3/α3 proteasome subunit.
Molecular Weight: Predicted: 28 kDa; Observed: 28 kDa on Western blots .
Function: Essential for ubiquitin-dependent protein degradation, critical for cellular homeostasis and stress response .
Developed by Nonet, M.L., Hadwiger, G., and Dour, S. at Washington University Medical School, the CePAS7 antibody was generated using:
Detects a single band at 28 kDa in C. elegans lysates, confirming specificity .
Validated in studies analyzing proteasome composition and function .
Localizes PAS-7 to the cytoplasm and nuclei in C. elegans whole-mount preparations .
Used to study proteasome dynamics during developmental stages .
Species Specificity: Unlike cross-reactive PAX7 antibodies (e.g., DSHB PAX7 targeting satellite cells in vertebrates) , CePAS7 is exclusive to C. elegans .
Structural Distinction: PAS-7 is unrelated to PAX7, a transcription factor regulating myogenesis .
This antibody remains a critical tool for studying proteasome biology in C. elegans, with standardized protocols ensuring reproducibility across studies . For methodology sections, cite:
CePAS7 was deposited to the DSHB by Nonet, M.L. / Hadwiger, G. / Dour, S. (DSHB Hybridoma Product CePAS7) .
Perform parallel experiments using:
Western blot: Compare wild-type vs. pas-7 knockout lysates. Expect a 28 kDa band only in wild-type samples .
Immunofluorescence: Use tissues with known PAS-7 expression (e.g., neuronal cells) and include isotype controls .
Competition assays: Pre-incubate antibody with recombinant PAS-7 protein (1:5 molar ratio) to confirm signal loss .
Case example: Discrepancies in 26S proteasome quantification may arise from:
Pulse-chase design: Incorporate MG132 (10 μM) to block proteasomal activity during pulse phase
Multiplex detection: Combine PAS-7 antibody with fluorogenic proteasome substrates (e.g., Suc-LLVY-AMC) for real-time activity correlation
Data normalization: Use β5 subunit levels as internal reference for proteasome quantification
Establish baseline: Map PAS-7 expression gradients in Wnt-activated vs. inhibited conditions (use CHIR99021/XAV939 treatments)
Employ co-immunoprecipitation with:
Validate findings using tissue-specific RNAi with ≥3 biological replicates
| Control Type | Implementation |
|---|---|
| Biological | pas-7(RNAi) and wild-type synchronized larvae |
| Technical | Spiked-in human 20S proteasome standards (10 ng/μL) |
| Procedural | Parallel samples without primary antibody |
Create standardized metrics:
| Metric | Calculation | Acceptable Range |
|---|---|---|
| Signal Specificity | (Knockout signal/WT signal) × 100 | ≤15% |
| Lot Consistency | CV across 3 antibody batches | ≤20% |
| Dynamic Range | Linear regression R² (1-100 ng load) | ≥0.98 |
Cryo-EM sample prep: Use PAS-7 localization patterns to guide particle picking in 26S proteasome reconstructions
Single-cell proteomics: Combine antibody staining with mass cytometry (CyTOF) using metal-tagged secondary reagents
Live imaging: Develop PAS-7 intrabodies fused with pH-sensitive fluorophores (e.g., pHluorin)